Skip to main content
CRS 2025 Annual Meeting & Exposition Main banner
Final Program


CRS Abstract Guide
Rate Poster

Nanomedicine and Nanoscale Delivery (Focus Group - NND)

(310) Engineering of innovative nanomedicine-microneedles for targeted auto-immune diseases therapy

Introduction:

Rheumatoid arthritis (RA) is a complex autoimmune disease leads to permanent joint damage, immobility and severe pain. Conventional therapies require prolonged courses and have side effects compromising the patient’s quality of life. This is a multiphase study innovatively targets the inflammatory mediation (Phase 1) and the reversal of activated fibroblasts by inhibiting signaling pathways and switching their pathogenic phenotype into quiescent ones (Phase 2). The main aim is to develop innovative localized nanomedicine-incorporated microneedles for improved personalized anti-RA therapy.

Learning Objectives:

  • Assess the nanomedicine-MNs as patient-friendly, localized treatments for RA.
  • Understand how targeted therapies revert activated SFs to a quiescent phenotype reverse RA damage.
  • Recognize the significance of personalized targeted strategies for precise delivery of therapeutics.
Ahmed Elzoghby – Instructor, Brigham and Women’s Hospital, Harvard Medical School, Harvard University, United States; Mariam Zewail – Assistant Professor, Department of Pharmaceutics, Faculty of Pharmacy, Damanhour University; Haidy Abbas – Assistant Professor, Department of Pharmaceutics, Faculty of Pharmacy, Damanhour University